Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand

Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.